Adial Pharmaceuticals, Inc. (ADIL)
- Previous Close
1.4450 - Open
1.4100 - Bid 1.4300 x 100
- Ask 1.4600 x 200
- Day's Range
1.3650 - 1.4700 - 52 Week Range
0.7700 - 14.0000 - Volume
119,598 - Avg. Volume
6,472,750 - Market Cap (intraday)
5.859M - Beta (5Y Monthly) 1.41
- PE Ratio (TTM)
-- - EPS (TTM)
-4.9100 - Earnings Date May 13, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
www.adialpharma.comRecent News: ADIL
Performance Overview: ADIL
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADIL
Valuation Measures
Market Cap
5.86M
Enterprise Value
3.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.24%
Return on Equity (ttm)
-190.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7M
Diluted EPS (ttm)
-4.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.83M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.21M
Research Analysis: ADIL
Company Insights: ADIL
ADIL does not have Company Insights